Home › Employers › ProMab Biotechnologies, Inc.
ProMab Biotechnologies, Inc.: H-1B salaries and sponsorship
ProMab Biotechnologies, Inc. filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 4. Median offered salary: $82,887.
Does ProMab Biotechnologies, Inc. sponsor H-1B visas?
ProMab Biotechnologies, Inc. filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Dec 3, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Research Associate | 3 | $75,774 |
| Research Scientist II | 1 | $112,882 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 1 | $60,757 |
| FY2025 | 2 | $94,328 |
| FY2026 | 1 | $90,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Research Associate | $90,000 Level I | Richmond, CA | Dec 3, 2025 | Dec 8, 2025 | Certified |
| Research Scientist II | $112,882–$117,872 Level II | Richmond, CA | Apr 15, 2025 | Oct 1, 2025 | Certified |
| Research Associate | $75,774–$80,104 Level III | Richmond, CA | Apr 1, 2025 | Oct 1, 2025 | Certified |
| Research Associate | $60,757–$67,000 Level II | Richmond, CA | May 3, 2024 | Oct 1, 2024 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).